Switch theme
Sign up to access all valuation multiples
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
2007
1.1K+
LTM Revenue n/a
LTM EBITDA n/a
$614M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dishman Carbogen Amics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Dishman Carbogen Amics achieved revenue of $295M and an EBITDA of $35.1M.
Dishman Carbogen Amics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dishman Carbogen Amics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $280M | $295M | XXX | XXX | XXX |
| Gross Profit | $195M | $219M | XXX | XXX | XXX |
| Gross Margin | 70% | 74% | XXX | XXX | XXX |
| EBITDA | $34.9M | $35.1M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 12% | XXX | XXX | XXX |
| Net Profit | $2.1M | -$3.5M | XXX | XXX | XXX |
| Net Margin | 1% | -1% | XXX | XXX | XXX |
| Net Debt | $152M | $196M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Dishman Carbogen Amics's stock price is INR 204 (or $2).
Dishman Carbogen Amics has current market cap of INR 32.1B (or $372M), and EV of INR 52.8B (or $614M).
See Dishman Carbogen Amics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $614M | $372M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Dishman Carbogen Amics has market cap of $372M and EV of $614M.
Dishman Carbogen Amics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Dishman Carbogen Amics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dishman Carbogen Amics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $614M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDishman Carbogen Amics's NTM/LTM revenue growth is n/a
Dishman Carbogen Amics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Dishman Carbogen Amics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dishman Carbogen Amics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dishman Carbogen Amics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 76% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dishman Carbogen Amics acquired XXX companies to date.
Last acquisition by Dishman Carbogen Amics was XXXXXXXX, XXXXX XXXXX XXXXXX . Dishman Carbogen Amics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Dishman Carbogen Amics founded? | Dishman Carbogen Amics was founded in 2007. |
| Where is Dishman Carbogen Amics headquartered? | Dishman Carbogen Amics is headquartered in India. |
| How many employees does Dishman Carbogen Amics have? | As of today, Dishman Carbogen Amics has 1.1K+ employees. |
| Is Dishman Carbogen Amics publicy listed? | Yes, Dishman Carbogen Amics is a public company listed on BOM. |
| What is the stock symbol of Dishman Carbogen Amics? | Dishman Carbogen Amics trades under 540701 ticker. |
| When did Dishman Carbogen Amics go public? | Dishman Carbogen Amics went public in 2004. |
| Who are competitors of Dishman Carbogen Amics? | Similar companies to Dishman Carbogen Amics include e.g. Jubilant Pharmova, Biocon, Syngene International, Suven Pharma. |
| What is the current market cap of Dishman Carbogen Amics? | Dishman Carbogen Amics's current market cap is $372M |
| What is the current revenue growth of Dishman Carbogen Amics? | Dishman Carbogen Amics revenue growth between 2023 and 2024 was 5%. |
| Is Dishman Carbogen Amics profitable? | Yes, Dishman Carbogen Amics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
